Nader Najafian, MD
Alnylam Pharmaceuticals
3
0
2
N/A
0
0
Research Impact
N/A
Research impact score
0
Total publications
0
Published trial results
0
Total citations
Drug Portfolio
Analytics
Trial Phases
Trial Status
Role Distribution
Activity Timeline
Clinical Trials (3)
Research Network
Collaboration Network
Research Areas & Affiliations
Therapeutic Areas
Affiliations
Similar Key Opinion Leaders
Discover other key opinion leaders with similar research profiles, therapeutic areas, and collaboration networks.
Oksana A. Markova, MD
AO GENERIUM
Shared therapeutic areas:
Steve Whitaker, MD
Omeros Corporation
Shared therapeutic areas:
George Chen
Roswell Park Cancer Institute
Shared therapeutic areas:
Oksana Markova, MD
AO GENERIUM
Shared therapeutic areas:
Karl E Anderson, MD
University of Texas
Shared therapeutic areas:
Karl E. Anderson, M.D.
University of Texas
Shared therapeutic areas:
Robert J. Desnick, Ph.D., M.D.
Icahn School of Medicine at Mount Sinai
Shared therapeutic areas:
yizhou zheng, doctor
Institute of Hematology & Blood Diseases Hospital, China
Shared therapeutic areas:
Rong Fu
Tianjin Medical University General Hospital
Shared therapeutic areas:
Brenda Sandmaier
Fred Hutch/University of Washington Cancer Consortium
Shared therapeutic areas:
Publications (0)
No publications found for this investigator.
Clinical Trials (3)
Showing 3 of 3 trials
A Study to Investigate the Interaction Between Givosiran and a 5-probe Drug Cocktail in Patients With Acute Intermittent Porphyria (AIP)
A Study of an Investigational Drug, Cemdisiran (ALN-CC5), in Patients With Atypical Hemolytic Uremic Syndrome
A Phase 1/2 Study of an Investigational Drug, ALN-CC5, in Healthy Adult Volunteers and Patients With PNH
All 3 trials loaded